Publications

Publications

WHO/Victor Garstea
© Credits

Latest publications

All →
Stronger health security through better disease prevention and control: Vaccine-preventable Diseases and Immunization Programme – 2025 in review

Vaccines save lives today and are key to preventing and controlling public health threats in the future. But their impact depends on consistent and sufficient...

Thirty-third Standing Committee of the Regional Committee for Europe: 16–17 June 2026: report of the fourth session

The fourth regular session of the Thirty-third Standing Committee of the Regional Committee for Europe (SCRC) took place in hybrid format in Reykjavík,...

Tobacco control playbook supplement: flavour bans are essential to protect young people from nicotine and tobacco products

The WHO European Region has made remarkable progress in tobacco control over recent decades, driven by the adoption and implementation of the WHO Framework...

Progress report of the Pan-European Network for Disease Control: April 2024–August 2025

Between April 2024 and August 2025, the Pan-European Network for Disease Control (NDC) evolved from a newly launched initiative into a regional platform...



Latest documents

All →

Tuberculosis and malnutrition factsheet

Overview

TB remains an important cause of mortality and morbidity in the WHO European Region and worldwide. Rates of drug-resistant TB are increasing globally. Malnutrition has significant interactions with the TB disease process and may be an important therapeutic target. There is a bidirectional relationship between TB and malnutrition: malnourished individuals are at greater risk of contracting TB, and TB is a catabolic disease that can cause or exacerbate malnutrition. TB patients who are malnourished experience poorer outcomes, which are more pronounced in those with RR/MDR-TB. Malnutrition impairs immune system function in multiple ways, and this may underpin some of the observed relationships. Furthermore, malnutrition can influence how drugs are absorbed and processed, causing treatment failure and downstream effects on treatment toxicity rates in TB patients.

WHO Team
Special Initiative on NCDs and Innovation (SNI)
Number of pages
10